150 related articles for article (PubMed ID: 38131551)
1. Safety and efficacy profile of intravitreal ranibizumab vs dexamethasone in treatment of naïve diabetic macular edema.
Mahapatra SK; Parhi A; Shree P; Mohanty A
Indian J Ophthalmol; 2024 Jan; 72(Suppl 1):S106-S110. PubMed ID: 38131551
[TBL] [Abstract][Full Text] [Related]
2. Intravitreal Dexamethasone Implant versus Intravitreal Ranibizumab Injection for Treatment of Non-Proliferative Diabetic Macular Edema: A Prospective, Randomized and Blinded Trial.
Mishra SK; Sinha S; Chauhan R; Kumar A
Curr Drug Deliv; 2021; 18(6):825-832. PubMed ID: 33267762
[TBL] [Abstract][Full Text] [Related]
3. Intravitreal steroids for macular edema in diabetes.
Rittiphairoj T; Mir TA; Li T; Virgili G
Cochrane Database Syst Rev; 2020 Nov; 11(11):CD005656. PubMed ID: 33206392
[TBL] [Abstract][Full Text] [Related]
4. A multicenter, 12-month randomized study comparing dexamethasone intravitreal implant with ranibizumab in patients with diabetic macular edema.
Callanan DG; Loewenstein A; Patel SS; Massin P; Corcóstegui B; Li XY; Jiao J; Hashad Y; Whitcup SM
Graefes Arch Clin Exp Ophthalmol; 2017 Mar; 255(3):463-473. PubMed ID: 27632215
[TBL] [Abstract][Full Text] [Related]
5. Comparison of early dexamethasone retreatment versus standard dexamethasone regimen combined with PRN ranibizumab in diabetic macular edema.
Arıkan Yorgun M; Toklu Y; Mutlu M
Int Ophthalmol; 2017 Feb; 37(1):185-196. PubMed ID: 27173834
[TBL] [Abstract][Full Text] [Related]
6. Anti-vascular endothelial growth factor combined with intravitreal steroids for diabetic macular oedema.
Mehta H; Hennings C; Gillies MC; Nguyen V; Campain A; Fraser-Bell S
Cochrane Database Syst Rev; 2018 Apr; 4(4):CD011599. PubMed ID: 29669176
[TBL] [Abstract][Full Text] [Related]
7. Comparison of the efficacy of intravitreal Anti-VEGF versus intravitreal dexamethasone implant in treatment resistant diabetic Macular Edema.
Koc H; Alpay A; Ugurbas SH
BMC Ophthalmol; 2023 Mar; 23(1):97. PubMed ID: 36915060
[TBL] [Abstract][Full Text] [Related]
8. Dexamethasone Implant in Chronic Diabetic Macular Edema Resistant to Intravitreal Ranibizumab Treatment.
Yucel OE; Can E; Ozturk HE; Birinci H; Sullu Y
Ophthalmic Res; 2017; 57(3):161-165. PubMed ID: 27926909
[TBL] [Abstract][Full Text] [Related]
9. Intravitreal Ranibizumab and Dexamethasone Implant Injections as Primary Treatment of Diabetic Macular Edema: The Month 24 Results from Simultaneously Double Protocol.
Kaya M; Atas F; Kocak N; Ozturk T; Ayhan Z; Kaynak S
Curr Eye Res; 2023 May; 48(5):498-505. PubMed ID: 36629472
[TBL] [Abstract][Full Text] [Related]
10. Visual Outcomes Following Intravitreal Ranibizumab for Diabetic Macular Edema in a Pro Re Nata Protocol from Baseline: A Real-World Experience.
James DGP; Mitkute D; Porter G; Vayalambrone D
Asia Pac J Ophthalmol (Phila); 2019; 8(3):200-205. PubMed ID: 31165603
[TBL] [Abstract][Full Text] [Related]
11. Comparison of intravitreal ranibizumab and aflibercept for the treatment of diabetic macular edema: a real-world study.
Isik P; Sizmaz S; Esen E; Uysal A; Demircan N
Int Ophthalmol; 2023 Nov; 43(11):4171-4180. PubMed ID: 37505290
[TBL] [Abstract][Full Text] [Related]
12. Dexamethasone implant as an adjuvant therapy to ranibizumab loading dose in persistent diabetic macular edema.
Cakir A; Erden B; Bolukbasi S; Bayat AH; Ozturan SG; Elcioglu MN
Int Ophthalmol; 2019 Oct; 39(10):2179-2185. PubMed ID: 30470985
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of retinal inflammatory biomarkers after intravitreal steroid implant and Ranibizumab injection in diabetic macular edema.
Muftuoglu IK; Tokuc EO; Sümer F; Karabas VL
Eur J Ophthalmol; 2022 May; 32(3):1627-1635. PubMed ID: 34219488
[TBL] [Abstract][Full Text] [Related]
14. Dexamethasone for unresponsive diabetic macular oedema: optical coherence tomography biomarkers.
Bonfiglio V; Reibaldi M; Pizzo A; Russo A; Macchi I; Faro G; Avitabile T; Longo A
Acta Ophthalmol; 2019 Jun; 97(4):e540-e544. PubMed ID: 30318792
[TBL] [Abstract][Full Text] [Related]
15. Early response to ranibizumab predictive of functional outcome after dexamethasone for unresponsive diabetic macular oedema.
Cicinelli MV; Cavalleri M; Querques L; Rabiolo A; Bandello F; Querques G
Br J Ophthalmol; 2017 Dec; 101(12):1689-1693. PubMed ID: 28432109
[TBL] [Abstract][Full Text] [Related]
16. Comparison of the effect of ranibizumab and dexamethasone implant in diabetic macular edema with concurrent epiretinal membrane.
Cakir A; Erden B; Bolukbasi S; Aydin A; Yurttaser Ocak S; Maden G; Elcioglu MN
J Fr Ophtalmol; 2019 Sep; 42(7):683-689. PubMed ID: 31088741
[TBL] [Abstract][Full Text] [Related]
17. Anti-VEGF versus dexamethasone implant (Ozurdex) for the management of Centre involved Diabetic Macular Edema (CiDME): a randomized study.
Sharma A; Bellala K; Dongre P; Reddy P
Int Ophthalmol; 2020 Jan; 40(1):67-72. PubMed ID: 31377905
[TBL] [Abstract][Full Text] [Related]
18. Comparison between intravitreal ranibizumab injection and posterior subtenon triamcinolone acetonide injection at time of cataract surgery for prevention of progression of diabetic macular edema.
Khalil MMAA; Mansour HO; Tawfik AMR; Elmahdy AG
BMC Ophthalmol; 2022 Dec; 22(1):492. PubMed ID: 36522705
[TBL] [Abstract][Full Text] [Related]
19. INTRAVITREAL DEXAMETHASONE IMPLANT IN PATIENTS WITH RANIBIZUMAB PERSISTENT DIABETIC MACULAR EDEMA.
Zhioua I; Semoun O; Lalloum F; Souied EH
Retina; 2015 Jul; 35(7):1429-35. PubMed ID: 26102440
[TBL] [Abstract][Full Text] [Related]
20. Use of intravitreal dexamethasone implant in patients with cataract and macular edema undergoing phacoemulsification.
Sze AM; Luk FO; Yip TP; Lee GK; Chan CK
Eur J Ophthalmol; 2015; 25(2):168-72. PubMed ID: 25363857
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
